HALO Earnings Halozyme Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | 1.22 | 2026-05-11 | 10-Q |
| FY 2025 | 2025-12-31 | 2.56 | 2026-02-17 | 10-K |
| Q3 2025 | 2025-09-30 | 3.68 | 2025-11-03 | 10-Q |
| Q2 2025 | 2025-06-30 | 2.26 | 2025-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | 0.93 | 2026-05-11 | 10-Q |
| FY 2025 | 2024-12-31 | 3.43 | 2026-02-17 | 10-K |
| Q3 2025 | 2024-09-30 | 2.37 | 2025-11-03 | 10-Q |
| Q2 2025 | 2024-06-30 | 1.32 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | 0.60 | 2025-05-06 | 10-Q |
| FY 2025 | 2023-12-31 | 2.10 | 2026-02-17 | 10-K |
| Q3 2024 | 2023-09-30 | 1.45 | 2024-10-31 | 10-Q |
| Q2 2024 | 2023-06-30 | 0.84 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | 0.29 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | 1.44 | 2025-02-18 | 10-K |
| Q3 2023 | 2022-09-30 | 1.02 | 2023-11-06 | 10-Q |
| Q2 2023 | 2022-06-30 | 0.58 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | 0.43 | 2023-05-09 | 10-Q |
| FY 2023 | 2021-12-31 | 2.74 | 2024-02-20 | 10-K |
| Q3 2022 | 2021-09-30 | 2.28 | 2022-11-08 | 10-Q |
| Q2 2022 | 2021-06-30 | 0.81 | 2022-08-09 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.